(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 October 2006 (19.10.2006)

PCT

(10) International Publication Number
WO 2006/108627 A1

(51) International Patent Classification:
C12Q 1/68 (2006.01) *C07K 16/28* (2006.01)

(21) International Application Number:
PCT/EP2006/003358

(22) International Filing Date: 12 April 2006 (12.04.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
05008156.1 14 April 2005 (14.04.2005) EP

(71) Applicant *(for all designated States except US)*: **MERCK PATENT GMBH** [DE/DE]; Frankfurter Strasse 250, 64293 Darmstadt 250 (DE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **SIENA, Salvatore** [IT/IT]; Ospedale Niguarda Ca'Granda, Divisione Oncologia Medica Falck, Piazza Ospedale Maggiore 3, I-20162 Milan (IT). **MORONI, Mauro** [IT/IT]; Ospedale Niguarda Ca'Granda, Divisione Oncologia Medica Falck, Piazza Ospedale Maggiore 3, I-20162 Milan (IT). **MARRAPESE, Giovanna** [IT/IT]; Ospedale Niguarda Ca'Granda, Divisione Oncologia Medica Falck, Piazza Ospedale Maggiore 3, I-20162 Milan (IT). **SARTORE-BIANCHI, Andrea** [IT/IT]; Ospedale Niguarda Ca'Granda, Divisione Oncologia Medica Falck, Piazza Ospedale Maggiore 3, I-20162 Milan (IT). **VERONESE, Silvio** [IT/IT]; Ospedale Niguarda Ca'Granda, Servizio Anatomia Patologica, Piazza Ospedale Maggiore 3, I-20162 Milan (IT). **GAMBACORTA, Marcello** [IT/IT]; Ospedale Niguarda Ca'Granda, Servizio Anatomia Patologica, Piazza Ospedale Maggiore 3, I-20162 Milan (IT). **BENVENUTI, Silvia** [IT/IT]; University of Torino Medical School, The Oncogenomics Center, Institute for Cancer Research and Treatment, I-10060 Candiolo (IT). **DI NICOLANTONIO, Federica** [IT/IT]; University of Torino Medical School, The Oncogenomics Center, Institute for Cancer Research and Treatment, I-10060 Candiolo (IT). **BARDELLI, Alberto** [IT/IT]; University of Torino Medical School, The Oncogenomics Center, Institute for Cancer Research and Treatment, I-10060 Candiolo (IT).

(74) Common Representative: **MERCK PATENT GMBH**; Frankfurter Strasse 250, 64293 Darmstadt 250 (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(48) Date of publication of this corrected version:
11 October 2007

(15) Information about Correction:
see PCT Gazette No. 41/2007 of 11 October 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTI-EGFR ANTIBODY THERAPY BASED ON AN INCREASED COPY NUMBER OF THE EGFR GENE IN TUMOR TISSUES

(57) Abstract: The invention relates to an individualized and personalized diagnosis and therapy of cancer based on specific molecular alterations which occur in specific tumor tissue of specific tumor patient populations. The therapy and diagnostic is based on the findings that proliferation and tumor growth of specific EGFR bearing tumor tissue expressing an amplified EGFR gene copy number may be abolished by anti-EGFR antibodies, while other individual molecular alterations such as mutations occurring in tumor tissues are unaffected by the same anti-EGFR antibody treatment.

WO 2006/108627 A1